Clinical Trials
16 trialsNCT06101394 2024-01-25
RECOGNISE
University of Turin, Italy
Phase 2 Unknown
NCT04648189 2023-10-19
Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC
The Netherlands Cancer Institute
Phase 2 Withdrawn
NCT00103207 2023-06-28
Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT02716311 2022-08-11
ACE-Lung
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Completed
NCT01059188 2022-03-11
Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC)
Swiss Cancer Institute
Phase 2 Completed
NCT00519831 2017-06-09
Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT00117962 2016-10-07
Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00323869 2016-09-07
Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer
Stanford University
Phase 2 Completed
NCT00124618 2016-07-06
Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01109524 2015-12-24
Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00081302 2015-11-17
Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer
Radiation Therapy Oncology Group
Phase 2 Completed
NCT00768131 2015-10-28
A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel
Eli Lilly and Company
Phase 2 Withdrawn
NCT00673738 2015-10-08
Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00193453 2012-11-13
Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00085501 2012-11-01
S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT00998101 2012-03-06
Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy
UNC Lineberger Comprehensive Cancer Center
Phase 2 Withdrawn